Bio:
Dr Urbanucci graduated from the University of Perugia, in Italy, and obtained a PhD in cancer genetics and molecular biology of cancer in Finland, at the University of Tampere, in 2012.
Dr. Urbanucci personal research interest is on the transcriptional and chromatin drivers underpinning prostate cancer progression with the androgen receptor as a focal point. He published a series of papers regarding the molecular effects of the deregulation of the androgen receptor on the chromatin and transcription, and how these effects drive prostate cancer progression.
He then moved to Oslo at the Centre for Molecular Medicine Norway (EMBL partnership), and subsequently at the Oslo University Hospital, where he investigated the mechanism of action of bromodomain inhibitors and derived novel prognostic tools for patient stratification. The work ongoing in this lab is the natural continuation of his work.
Original articles
Inhibition of O-GlcNAc Transferase Renders Prostate Cancer Cells Dependent on CDK9
Mol Cancer Res, 18 (10), 1512-1521
DOI 10.1158/1541-7786.MCR-20-0339, PubMed 32611550
Dysregulation of MITF Leads to Transformation in MC1R-Defective Melanocytes
Cancers (Basel), 12 (7)
DOI 10.3390/cancers12071719, PubMed 32605315
Loss of Snord116 impacts lateral hypothalamus, sleep, and food-related behaviors
JCI Insight, 5 (12)
DOI 10.1172/jci.insight.137495, PubMed 32365348
AR and ERG drive the expression of prostate cancer specific long noncoding RNAs
Oncogene, 39 (30), 5241-5251
DOI 10.1038/s41388-020-1365-6, PubMed 32555329
Drivers of AR indifferent anti-androgen resistance in prostate cancer cells
Sci Rep, 9 (1), 13786
DOI 10.1038/s41598-019-50220-1, PubMed 31551480
The β2-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells
Mol Cancer Res, 17 (11), 2154-2168
DOI 10.1158/1541-7786.MCR-18-0605, PubMed 31395667
High OGT activity is essential for MYC-driven proliferation of prostate cancer cells
Theranostics, 9 (8), 2183-2197
DOI 10.7150/thno.30834, PubMed 31149037
Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories
Cancer Cell, 34 (6), 996-1011.e8
DOI 10.1016/j.ccell.2018.10.016, PubMed 30537516
The expression of AURKA is androgen regulated in castration-resistant prostate cancer
Sci Rep, 7 (1), 17978
DOI 10.1038/s41598-017-18210-3, PubMed 29269934
Lipid degradation promotes prostate cancer cell survival
Oncotarget, 8 (24), 38264-38275
DOI 10.18632/oncotarget.16123, PubMed 28415728
Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer
Cell Rep, 19 (10), 2045-2059
DOI 10.1016/j.celrep.2017.05.049, PubMed 28591577
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks
EBioMedicine, 18, 83-93
DOI 10.1016/j.ebiom.2017.04.006, PubMed 28412251
Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer
BMC Genomics, 18 (1), 270
DOI 10.1186/s12864-017-3620-y, PubMed 28359301
Cell cycle-coupled expansion of AR activity promotes cancer progression
Oncogene, 36 (12), 1655-1668
DOI 10.1038/onc.2016.334, PubMed 27669432
CTCF modulates Estrogen Receptor function through specific chromatin and nuclear matrix interactions
Nucleic Acids Res, 44 (22), 10588-10602
DOI 10.1093/nar/gkw785, PubMed 27638884
Changes of 5-hydroxymethylcytosine distribution during myeloid and lymphoid differentiation of CD34+ cells
Epigenetics Chromatin, 9, 21
DOI 10.1186/s13072-016-0070-8, PubMed 27252783
CIP2A is a candidate therapeutic target in clinically challenging prostate cancer cell populations
Oncotarget, 6 (23), 19661-70
DOI 10.18632/oncotarget.3875, PubMed 25965834
Myc-dependent purine biosynthesis affects nucleolar stress and therapy response in prostate cancer
Oncotarget, 6 (14), 12587-602
DOI 10.18632/oncotarget.3494, PubMed 25869206
Slug-dependent upregulation of L1CAM is responsible for the increased invasion potential of pancreatic cancer cells following long-term 5-FU treatment
PLoS One, 10 (4), e0123684
DOI 10.1371/journal.pone.0123684, PubMed 25860483
Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate
Prostate, 73 (1), 101-12
DOI 10.1002/pros.22545, PubMed 22674191
Chemical castration and anti-androgens induce differential gene expression in prostate cancer
J Pathol, 227 (3), 336-45
DOI 10.1002/path.4027, PubMed 22431170
Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer
Oncogene, 31 (41), 4460-71
DOI 10.1038/onc.2011.624, PubMed 22266859
Androgen receptor overexpression alters binding dynamics of the receptor to chromatin and chromatin structure
Prostate, 72 (11), 1223-32
DOI 10.1002/pros.22473, PubMed 22212979
Overexpression of androgen receptor enhances the binding of the receptor to the chromatin in prostate cancer
Oncogene, 31 (17), 2153-63
DOI 10.1038/onc.2011.401, PubMed 21909140
Androgen regulation of micro-RNAs in prostate cancer
Prostate, 71 (6), 604-14
DOI 10.1002/pros.21276, PubMed 20945501
Potential internalisation of caliciviruses in lettuce
Int J Food Microbiol, 135 (2), 175-8
DOI 10.1016/j.ijfoodmicro.2009.07.036, PubMed 19720414
Androgen regulation of the androgen receptor coregulators
BMC Cancer, 8, 219
DOI 10.1186/1471-2407-8-219, PubMed 18673534
Review articles
Chromatin reprogramming as an adaptation mechanism in advanced prostate cancer
Endocr Relat Cancer, 26 (4), R211-R235
DOI 10.1530/ERC-18-0579, PubMed 30844748
Bromodomain-containing proteins in prostate cancer
Mol Cell Endocrinol, 462 (Pt A), 31-40
DOI 10.1016/j.mce.2017.06.007, PubMed 28624514
Androgen-regulated metabolism and biosynthesis in prostate cancer
Endocr Relat Cancer, 21 (4), T57-66
DOI 10.1530/ERC-13-0515, PubMed 24497572
Androgen receptor (AR) aberrations in castration-resistant prostate cancer
Mol Cell Endocrinol, 360 (1-2), 38-43
DOI 10.1016/j.mce.2011.12.019, PubMed 22245783